SCHEMBL2922769

SCHEMBL2922769

Cc1cccc2cnc(Nc3cccc(O)c3)nc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.67
CDK2 P24941 4/20 0.48
CDK4 P11802 3/20 0.48
CDK1 P06493 2/20 0.48
CCNB1 P14635 2/20 0.48
CCND1 P24385 2/20 0.48
CCNE1 P24864 2/20 0.48
CCNT1 O60563 2/20 0.48
CDK9 P50750 2/20 0.48
CDK7 P50613 1/20 0.48
CCNH P51946 1/20 0.48
RAPGEF4 Q8WZA2 1/20 0.48
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
PDGFRB P09619 1/20 0.47
FGFR1 P11362 1/20 0.47
SRC P12931 1/20 0.47
PDGFRA P16234 1/20 0.47
MAPK14 Q16539 1/20 0.47
CCNA2 P20248 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12999378 0.86 AURKA (0.60) SYKCDK2CDK4CDK1CCNB1
SCHEMBL2916705 0.85 KDR (0.52) SYKCDK2CDK4CDK1CCNB1
SCHEMBL2913599 0.83 KDR (0.56) SYKCDK2CDK4CDK1CCNB1
SCHEMBL2911814 0.83 MAPK10 (0.53) SYKCDK2CDK4CDK1CCNB1
SCHEMBL2912369 0.83 SYK (0.56) SYKCDK2CDK4ABL1SRC
SCHEMBL12999377 0.83 ABL1 (0.58) SYKCDK2CDK4RAPGEF4ABL1
SCHEMBL2919611 0.83 L3MBTL1 (0.51) SYKCDK2CDK4CDK1CCNB1
Hydrochloric Acid SCHEMBL2916265 0.82 ABL1 (0.57) SYKCDK2CDK4RAPGEF4ABL1
SCHEMBL2920795 0.82 RHOA (0.57) SYKABL1EGFRFGFR1AURKA
SCHEMBL2919202 0.82 MAP3K5 (0.70) SYKABL1EGFRPDGFRBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K SYK 724/4885CDK2 15/4885CDK4 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.